Risk Factors Update Summary
- Phase 1a clinical trial for SZN-043 was completed in February 2024, with Grade 1 and 2 treatment-related adverse events observed.
- Replaced "you" with "holders of public warrants" to clarify potential consequences for investors.
- Additional capital may be required to complete clinical trial and development efforts for SZN-043.
- Changed "Common Stock" to "common stock" throughout the risk factors section.
- The company entered into an at-the-market sales agreement with Guggenheim Securities, LLC, for up to $23.0 million.
- Replaced "Public Warrants" with "public warrants" in multiple instances for consistency.
- The company implemented restructuring plans to reduce the overall workforce by approximately 38%.
- Officers and directors control 31.1% of common stock, potentially influencing matters requiring approval.
- The company may issue additional shares of common stock or equity securities, diluting ownership interest.
- The company may amend the terms of Public Warrants without approval, impacting exercise price and period.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1824893&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.